Semaglutide for Post-Smoking Cessation Weight Management

NCT06173778

Status	RECRUITING
Phase	Phase 2
Sponsor	The University of Texas Health Science Center, Houston
Enrollment	197 participants

Key Eligibility Criteria

Inclusion (8)

- Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study.
- Body mass index (BMI) e30 kg/m2 or e27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical exclusion criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea
- Have been smoking e5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test.
- Desire to quit smoking (defined as "intend to quit within one month")
- Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).

... and 3 more (see full listing online)

Exclusion (44)

- Medical Exclusions
- Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Acute pancreatitis within the past 6 months prior to screening.
- History or presence of chronic pancreatitis.
- Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C e48 mmol/mol (6.5%) as measured by central laboratory at screening).

... and 39 more (see full listing online)

Locations (2 total)

The University of Texas at Austin, Austin, Texas, United States
The University of Texas Health Science Center at Houston, Houston, Texas, United States